Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.

Chao, Joseph; Fuchs, Charles; Shitara, Kohei; Tabernero, Josep; Muro, Kei; Van Cutsem, Eric; Bang, Yung-Jue; De Vita, Ferdinando; Landers, Gregory; Yen, Chia-Jui; Chau, Ian; Elme, Anneli; Lee, Jeeyun; Özgüroglu, MUSTAFA; Catenacci, Daniel; Yoon, Harry; Chen, Erluo; Adelberg, David; Shih, Chie-Schin; Shah, Sukrut; Bhagia, Pooja; Wainberg, Zev

doi:10.1001/jamaoncol.2021.0275

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.

Chao J., Fuchs C. S., Shitara K., Tabernero J., Muro K., Van Cutsem E., ...Daha Fazla

JAMA oncology, cilt.7, ss.895-902, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 7
Basım Tarihi: 2021
Doi Numarası: 10.1001/jamaoncol.2021.0275
Dergi Adı: JAMA oncology
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
Sayfa Sayıları: ss.895-902
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

IMPORTANCE Immunotherapy has been associated with improved outcomes among patients who have received previous treatment for microsatellite instability-high (MSI-H) tumors.